280 related articles for article (PubMed ID: 17642003)
1. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
2. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
3. In biomarkers we trust?
Baker M
Nat Biotechnol; 2005 Mar; 23(3):297-304. PubMed ID: 15765081
[No Abstract] [Full Text] [Related]
4. Molecular biomarkers in drug development.
Lewin DA; Weiner MP
Drug Discov Today; 2004 Nov; 9(22):976-83. PubMed ID: 15539141
[TBL] [Abstract][Full Text] [Related]
5. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
6. Molecular diagnostics: an FDA perspective.
Ardekani AM; Petricoin EF; Hackett JL
Expert Rev Mol Diagn; 2003 Mar; 3(2):129-40. PubMed ID: 12647991
[TBL] [Abstract][Full Text] [Related]
7. Attrition and translation.
Duyk G
Science; 2003 Oct; 302(5645):603-5. PubMed ID: 14576424
[TBL] [Abstract][Full Text] [Related]
8. [Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase/2nd communication: promising strategies].
Kuhlmann J
Arzneimittelforschung; 2004; 54(6):307-13. PubMed ID: 15282874
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in biomarkers for cancer diagnosis and treatment.
Manne U; Srivastava RG; Srivastava S
Drug Discov Today; 2005 Jul; 10(14):965-76. PubMed ID: 16023055
[TBL] [Abstract][Full Text] [Related]
10. The brains behind blockbusters.
Couzin J
Science; 2005 Jul; 309(5735):728. PubMed ID: 16051786
[No Abstract] [Full Text] [Related]
11. Cutting the cost of drug development?
Rawlins MD
Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
[No Abstract] [Full Text] [Related]
12. Using imaging biomarkers to accelerate drug development and clinical trials.
Pien HH; Fischman AJ; Thrall JH; Sorensen AG
Drug Discov Today; 2005 Feb; 10(4):259-66. PubMed ID: 15708744
[TBL] [Abstract][Full Text] [Related]
13. Clinical biomarkers in drug discovery and development.
Frank R; Hargreaves R
Nat Rev Drug Discov; 2003 Jul; 2(7):566-80. PubMed ID: 12838269
[TBL] [Abstract][Full Text] [Related]
14. Molecular approaches to the identification of biomarkers of exposure and effect--report of an expert meeting organized by COST Action B15. November 28, 2003.
Gundert-Remy U; Dahl SG; Boobis A; Kremers P; Kopp-Schneider A; Oberemm A; Renwick A; Pelkonen O
Toxicol Lett; 2005 Apr; 156(2):227-40. PubMed ID: 15737486
[TBL] [Abstract][Full Text] [Related]
15. Surviving the blockbuster syndrome.
Service RF
Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
[No Abstract] [Full Text] [Related]
16. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
Park JW; Kerbel RS; Kelloff GJ; Barrett JC; Chabner BA; Parkinson DR; Peck J; Ruddon RW; Sigman CC; Slamon DJ
Clin Cancer Res; 2004 Jun; 10(11):3885-96. PubMed ID: 15173098
[No Abstract] [Full Text] [Related]
17. The proteomics bottleneck: strategies for preliminary validation of potential biomarkers and drug targets.
Bodovitz S; Joos T
Trends Biotechnol; 2004 Jan; 22(1):4-7. PubMed ID: 14690616
[No Abstract] [Full Text] [Related]
18. Discovery and development of biomarkers of neurological disease.
Dunckley T; Coon KD; Stephan DA
Drug Discov Today; 2005 Mar; 10(5):326-34. PubMed ID: 15749281
[TBL] [Abstract][Full Text] [Related]
19. Productivity counts--but the definition is key.
Mervis J
Science; 2005 Jul; 309(5735):726. PubMed ID: 16051784
[No Abstract] [Full Text] [Related]
20. Molecular genetics: the Emperor's clothes of drug discovery?
Higgs G
Drug Discov Today; 2004 Sep; 9(17):727-9. PubMed ID: 15450232
[No Abstract] [Full Text] [Related]
[Next] [New Search]
